<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058912</url>
  </required_header>
  <id_info>
    <org_study_id>UU-MREC-2019-5/28</org_study_id>
    <nct_id>NCT04058912</nct_id>
  </id_info>
  <brief_title>PTEN-AKT-FOXO3 Gene Expression Relation With Low-ovarian Reserve in Endometriomas</brief_title>
  <official_title>RELATIONSHIP OF LOW-OVER RESERVE WITH PTEN-AKT-FOXO3 GENE EXPRESSION IN THE PRESENCE OF ENDOMETRIOMAS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uludag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we aimed to investigate the relationship between PTEN-AKT-FOXO3 gene
      expression and decrease in ovarian reserve in the presence of endometrioma and other benign
      ovarian pathologies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that the presence of endometrioma negatively affects ovarian reserve. The
      development of endometriosis and the effect of the presence of endometrioma on ovarian
      reserve due to decreased PTEN expression are considered. This study was designed to compare
      ovarian PTEN-AKT-FOXO3 gene expression and ovarian reserve in patients with underwent surgery
      caused by endometrioma and those who had ovarian pathology due to other benign causes and
      PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PTEN AKT FOXO3 gene expression</measure>
    <time_frame>30 minutes</time_frame>
    <description>In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Reserve, Endometrioma, PTEN-AKT-FOXO3 Gene Expression</condition>
  <arm_group>
    <arm_group_label>PATİENCE GROUP</arm_group_label>
    <description>To be in the range of 18-40 years
Patients with an operation indication with &gt;=5 cm endometrioma
Symptomatic patients due to endometrioma (dysmenorrhea, dyspareunia, chronic pelvic pain, etc.)
Patients who will be followed for IVF cycle due to infertility</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATİENCE-CONTROL GROUP</arm_group_label>
    <description>To be in the range of 18-40 years
Patients with operation plan due to non-endometrioma ovarian pathologies
Symptomatic patients with benign ovarian pathology (such as chronic pelvic pain, compression, syphilomas, dysmenorrhea, dyspareunia, etc.)
Asymptomatic, despite a 6-month follow-up period, increase in cyst size or become symptomatic</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>PTEN-AKT-FOXO3 Gene Expression</intervention_name>
    <description>In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.</description>
    <arm_group_label>PATİENCE GROUP</arm_group_label>
    <arm_group_label>PATİENCE-CONTROL GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is the patients examined for ovarian endometriomas and other benign
        ovarian pathologies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) To be in the range of 18-40 years 2) Patients with an operation indication with &gt;=5
             cm endometrioma 3) Patients with operation plan due to non-endometrioma ovarian
             pathologies

        Exclusion Criteria:

          -  1)Patients over the age of 40 2)Patients with suspected malignancy 3)Follow-up
             patients without indications for operation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>GURKAN UNCU, Prof</last_name>
    <role>Study Director</role>
    <affiliation>ULUDAG UNIVERSITY HOSPITAL BURSA TURKEY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HAMZA F SEN, MD</last_name>
    <phone>+90 544 3939159</phone>
    <email>hamzafurkansen@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isil Kasapoglu, MD</last_name>
    <phone>+905305455848</phone>
    <email>kasapogluisil@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uludag University Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Bursa</city>
        <state>Nilufer</state>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HAMZA F SEN, MD</last_name>
      <phone>+90 5443939159</phone>
      <email>hamzafurkansen@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Isil Kasapoglu, MD</last_name>
      <phone>+905305455848</phone>
      <email>kasapogluisil@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uludag University Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Bursa</city>
        <state>Nilufer</state>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.FURKAN MD SEN</last_name>
      <phone>+90 5443939159</phone>
      <email>hamzafurkansen@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Isil MD Kasapoglu</last_name>
      <phone>+905305455848</phone>
      <email>kasapogluisil@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Govatati S, Kodati VL, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M. Mutations in the PTEN tumor gene and risk of endometriosis: a case-control study. Hum Reprod. 2014 Feb;29(2):324-36. doi: 10.1093/humrep/det387. Epub 2013 Oct 23.</citation>
    <PMID>24154570</PMID>
  </reference>
  <reference>
    <citation>Kasapoglu I, Ata B, Uyaniklar O, Seyhan A, Orhan A, Yildiz Oguz S, Uncu G. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018 Jul 1;110(1):122-127. doi: 10.1016/j.fertnstert.2018.03.015. Epub 2018 Jun 20.</citation>
    <PMID>29935810</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uludag University</investigator_affiliation>
    <investigator_full_name>GÜRKAN UNCU,PROF. MD</investigator_full_name>
    <investigator_title>: Principal Investigator. Professor, Obstetrician and Gynecologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

